DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Anthrax vaccine is an investigational drug.
There have been 14 clinical trials for Anthrax vaccine. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2015.
The most common disease conditions in clinical trials are Anthrax, Cystitis, and Cystic Fibrosis. The leading clinical trial sponsors are Department of Health and Human Services, Bayer, and National Institute of Allergy and Infectious Diseases (NIAID).
There are twelve US patents protecting this investigational drug and fifty-five international patents.
Recent Clinical Trials for Anthrax vaccine
|Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study||Biomedical Advanced Research and Development Authority||Phase 2|
|Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study||Emergent Product Development Gaithersburg, Inc.||Phase 2|
|BARDA Securing Anthrax Immunity For the Elderly||Rho, Inc.||Phase 2|
Top disease conditions for Anthrax vaccine
Top clinical trial sponsors for Anthrax vaccine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Anthrax vaccine||Start Trial||Albumin derivatives and variants||ALBUMEDIX LTD (Nottingham, GB)||Start Trial|
|Anthrax vaccine||Start Trial||Flagellin-based agents and uses including effective vaccination||GENOME PROTECTION, INC. (Buffalo, NY)||Start Trial|
|Anthrax vaccine||Start Trial||Temperature stable vaccine formulations||Emergent Product Development Gaithersburg Inc. (Gaithersburg, MD)||Start Trial|
|Anthrax vaccine||Start Trial||Bioadhesive delivery system for transmucosal delivery of beneficial agents||SRI International (Menlo Park, CA)||Start Trial|
|Anthrax vaccine||Start Trial||Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides||The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (N/A)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Anthrax vaccine||China||102939304||2030-04-09||Start Trial|
|Anthrax vaccine||China||106977608||2030-04-09||Start Trial|
|Anthrax vaccine||European Patent Office||2556087||2030-04-09||Start Trial|
|Anthrax vaccine||Japan||2013523145||2030-04-09||Start Trial|
|Anthrax vaccine||Japan||2017031136||2030-04-09||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|